TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05647096: Safety, Tolerability and Performance of the NucleoCapture Extracorporeal Therapeutic Apheresis Device in the Reduction of Circulating CfDNA/NETs in Subjects with Sepsis

Sponsor: Santersus AG · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 73 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,027,400

Rescue Site Savings

+$3,322,200

Unlock Full NCT05647096 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05647096 Rescue Dossier →